Previous reports have shown that pharmacological manipulation of Nrf2 pathway activation can alleviate ARDS by inhibiting ROS production and NLRP3 inflammasome-mediated pyroptosis[53]. Here, NLRP3 is linked to acute respiratory distress syndrome.